沉默调节蛋白家族：治疗衰老相关疾病的靶点
The Sirtuin family: therapeutic targets to treat diseases of aging.
作者信息
Milne Jill C, Denu John M
机构信息
Sirtris Pharmaceuticals, Inc., 790 Memorial Drive, Cambridge, MA 02139, USA.
出版信息
Curr Opin Chem Biol. 2008 Feb;12(1):11-7. doi: 10.1016/j.cbpa.2008.01.019. Epub 2008 Mar 7.
Sirtuins have emerged as therapeutic targets to treat age-related diseases. There are seven human Sirtuins (SIRT1-7) that display diversity in cellular localization and function. Growing evidence suggests that small-molecule activators of SIRT1 may counteract age-related afflictions such as type 2 diabetes. Alternatively, inhibitors of SIRT2 may be useful in the treatment of neurodegenerative diseases such as Parkinson's disease. Recent discoveries of small-molecule and protein modulators of Sirtuin deacetylation activity have provided enormous insight into the biological and molecular functions of Sirtuins and have validated their potential as therapeutics.
沉默调节蛋白已成为治疗与年龄相关疾病的治疗靶点。人类有七种沉默调节蛋白（SIRT1 - 7），它们在细胞定位和功能上表现出多样性。越来越多的证据表明，SIRT1的小分子激活剂可能对抗诸如2型糖尿病等与年龄相关的疾病。另外，SIRT2的抑制剂可能有助于治疗诸如帕金森病等神经退行性疾病。最近对沉默调节蛋白去乙酰化活性的小分子和蛋白质调节剂的发现，为沉默调节蛋白的生物学和分子功能提供了极大的见解，并验证了它们作为治疗药物的潜力。
Zotero 插件